anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Autophagy is closely associated with the onset and progression of steroid-induced osteonecrosis of the femoral head (SIONFH). SQSTM1/p62 is an important indicator of autophagic activity. The aim of this study was to investigate the role of SQSTM1/p62 in the development of SIONFH. From May 2021 through November 2021, 36 patients diagnosed with SIONFH and 36 healthy controls were recruited for this study. Evaluations included imaging and pathologic assessment of clinical bone tissue, location and level of SQSTM1/p62 expression, plasma SQSTM1/p62 levels, and receiver operating characteristic (ROC) curves. We observed that the expression level of SQSTM1/p62 in bone samples decreased with the Association Research Circulation Osseous (ARCO) phase. Plasma SQSTM1/p62 levels were significantly higher in the SIONFH group compared to healthy controls. Plasma SQSTM1/p62 levels were higher in pre-crash patients than in post-crash patients, and lower plasma SQSTM1/p62 levels were associated with elevated ARCO stage. Plasma SQSTM1/p62 may represent a potential biomarker for different stages during SIONFH. Lower plasma SQSTM1/p62 levels indicate an advanced stage of SIONFH. This study provides new clues for early diagnosis of SIONFH.
SYMBICORT should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma or COPD. SYMBICORT has not been studied in patients with acutely deteriorating asthma or COPD. The initiation of SYMBICORT in this setting is not appropriate.

Increasing use of inhaled, short-acting beta2-agonists is a marker of deteriorating asthma. In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of SYMBICORT with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. Patients should not use more than 2 inhalations twice daily (morning and evening) of SYMBICORT.

SYMBICORT should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. An inhaled, short-acting beta2-agonist, not SYMBICORT, should be used to relieve acute symptoms such as shortness of breath. 

When beginning treatment with SYMBICORT, patients who have been taking oral or inhaled, short-acting beta2-agonists on a regular basis (e.g., 4 times a day) should be instructed to discontinue the regular use of these drugs.
In brief, a fornix-based conjunctival incision is followed by fashioning and dissection of a triangular scleral flap. Radial incisions at the limbus followed to identify Schlemm's canal. viscotrabeculotomy, is performed by injection of high-viscosity sodium hyaluronate (Healon GV, Pfizer, NY) into Schlemm's canal prior to completion of the procedure with the metal trabeculotome. while a Nylon 10/0 suture in inserted into schlemm's canal in visco-circumferential-suture trabeculotomy group.
A method of treating conditions that are characterised by a deficiency in the number and function of membrane bound receptors. Such conditions include Alzheimer's disease, senile dementia (of the Alzheimer's type), Parkinson's disease, postural hypotension, chronic fatigue syndrome, Lewing-Bedy disease, Gulf War syndrome, autism, Myasthenia Gravis, Lambert Eaton disease, exposure to organo-phosphorus compounds and age-related problems of muscle and heart fibre. The mechanism of how these diseases are related to the number and function of membrane bound receptors is described in detail. Saponins and sapogenins, such as anzurogenin D, diosgenin, hecogenin, prazerigenin, ruscogenin, smilagenin, sisalogenin, sarsasapogenin, tigogenin or astragaloside, exhibit the ability to regulate receptor activity. Their ability to regulate the number and function of membrane bound receptors (muscarinic receptors) was studied in chinese hamster ovary cells and in cultured cardiac cells. Non-oestrogenic saponins and sapogenins are the preferred compounds. Saponins and sapogenins of this type were also claimed to have cognitive function enhancing properties when used to treat age-related cognitive dysfunction. These compounds may be derived from a plant of the genus Agave, Anemarrhena, Asparagus, Smilax or Yucca.
Post-operative chronic pain can be defined as the neuropathic-characterized pain persisting at least 3 months after the surgery despite healing of the operation area.

However, it is still uncertain if the underlying physio-pathologic mechanism is due to intraoperative direct nerve injury or it is resulting from indirect nerve injury caused by inflammatory mesh. Post-operative chronic pain restricts the daily activities, causes anxiety and depression, increases use of analgesics and imposes a serious economic burden by increased use of health services and medical treatment. For this reason, today post-operative chronic pain is considered as an important complication of surgery. Researchers can list the risk factors of pain development as; age, weight, preoperative and postoperative pain, surgical method, recurrence, anesthesia method. Various oral non-steroid and/or opioid agents have been used in chronic pain treatment but nowadays interest in regional anesthesia approaches is increasing due to increased systemic side effects. Aim in this study is to evaluate the effects of postoperative ilioinguinal block implementation on chronic pain in patients who will undergo inguinal hernia operation with spinal anesthesia.
Self-Management #2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average). The sessions will cover a variety of topics, including: (1) the definition of chronic pain, (2) the physiological processes underlying chronic pain, (3) common pain-related conditions such as sleep and mood disturbance (including posttraumatic stress disorder, due to its prevalence among Veterans), (4) the potential effects of chronic pain on activity level, (5) communication (including communication with healthcare providers), and (6) the role of social support in managing pain.
In recent time in Bhutan P.vivax infection is on rise compared to other types of malaria like P.falciparum which used to be the most common infections. May be this is mainly due to intensive measures taken place in controlling the diseases especially vector control measures. So that way P.falciparum has gone now. But on other hand P.vivax has peaked the infection. The main reason could be due to resistant to Chloroquine or may be Chloroquine dose is inadequate, and it could also mean it could be due to relapses from the hypnozoites stage where Primaquine dose could be inadequate. Therefore this study is developed to study the efficacy of Chloroquine alone withholding Primaquine for day 28 slightly deviating from the current treatment protocol of Bhutan. That parasitic clearance and recurrence rates will be recorded while on Chloroquine and Primaquine separately. For those patients whose blood stage of parasites doesnt get cleared with standard dose of Chloroquine or for any recurrences occurring before day 28, will be treated with second line treatment with ACT, and the blood level of Chloroquine(drug concentration) will be determined to say whether that could be due to resistance or due to low level of Chloroquine in the blood. And for any recurrences occurring after day 28 while of Primaquine or after completion of Primaquine dosage for a total of 14 days (from day 29 to day 42) those patients will be treated in a similar fashion as initial treatment with Chloroquine and Primaquine and the recurrence rates will be recorded so as to develop next level of study where two different doses of Primaquine (high dose vs low dose) will be compared to study the efficacy of Primaquine.
The goal of this to identify the facilitators and barriers among caregivers in the emergency department (ED) that influence disposition of patients with solid and hematology malignancies. Participants will be asked for permission, afterwards a short interview will be held with the different caregivers (ED nurse, attending physician and supervising physician) in the ED. The interviews will be held in the order of the ED care pathway, meaning ED nurse first, treating physician second and supervising physician at last. The interviews will be conducted for every patient with each of the caregivers. Each interview will be conducted after the caregiver has made the first examination of the patient. The interview focuses on several parts of the emergency care process: The first part is regarding the actions that are executed during an ED visit. We will establish which actions are executed and why. The second part is regarding the suspected outcome for the patient. The third part will be about any potential improvements to the emergency care process for the patient.
Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1, 8, and 15 and durvalumab IV over 60 minutes on days 8 and 22 of cycles 1 and 2 and day 8 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who discontinue gemcitabine hydrochloride continue receiving durvalumab alone as in Arm I. Patients undergo CT throughout the trial. Patients also undergo tissue biopsy and blood sample collection during screening and on the trial.
The treatment period is 12 weeks as a treatment unit, starting from the first day of baseline, subcutaneous injection of Peg-IFNα-2b 180μg once a week, the total treatment course does not exceed 96 weeks. During treatment, when any efficacy check point reaches the disappearance of HBsAg with or without the appearance of HBsAb, at least 2 treatment units of consolidation therapy are given and then the drug is discontinued. Observed for 24 weeks after treatment.
In one embodiment, a method comprises identifying one or more health-care-providers associated with one or more medical-specializations, wherein each medical-specialization is associated with a specialty class and at least one geographic area. A number of patient-diagnosis codes is received, each patient-diagnosis code corresponding to one of the health-care-providers and representing a patient-visit to the health-care-provider. The patient-diagnosis code includes at least one diagnosis within a condition-group for the patient visit, and a severity-factor for the diagnosis. The method further comprises determining all patient-diagnosis codes corresponding to the health-care-providers. A patient-volume is calculated for each health-care-provider, based on the patient-diagnosis codes and associated severity-factors. A variety-score is calculated for each health-care-provider based on the patient-diagnosis codes. An experience-score is calculated for each health-care-provider based on the patient-volume and variety-score.
Despite broad awareness of the role that diet plays in increasing obesity risk, adherence to public health recommendations for maintaining healthy eating is low. Insights gained from weight loss intervention trials find that trial participants report difficulty in restricting calories, dissatisfaction with the pace of weight loss, inability to control eating, low palatability of recommended foods and strong food cravings. Indeed, recent systematic reviews provide empirical support that these subjective experiences that trial participants describe likely represent eating-related traits or phenotypes . While amassing evidence supports individual variation in these eating-related traits, to date there has been no systematic effort to characterize robust eating-related phenotypes. Proposed is a Sub-study initially planned to be piggy-backed on a planned Study being conducted by investigators at the University of North Carolina (UNC-- Linnan, Dilworth- Anderson \& Evans). The UNC Parent Study was a feasibility study using community-based participatory research (CBPR) approaches to explore possible intervention strategies aimed to reduce the burden of chronic disease and cancer among African American families. The NHGRI-led eating behavior Sub-study is proposed to be integrated with the UNC Parent Study (hereafter referred to as Phase 1). The additional aims of the Sub-study (hereafter referred to as Phase 2) are to gain understanding of whether we can characterize clusters of eating-related behaviors that may be associated with adherence to weight management and weight outcomes. This current protocol lays out the specific qualitative activities planned for Phase 1 which include conducting structured interviews with Black Family Reunion organizers (N=8) and a sample of reunion participants (N=40). We also describe the larger quantitative survey proposed for Phase 2. Pending the feasibility of the sub-study with the African-American community, we will collect information on eating-related behaviors in a large sample of individuals (N=350). If the initial assessments (Phase1) prove that this is not a viable study to be conducted in that setting, we will consider other population groups and other settings.

We are also considering Phase 3 activities if we identify clusters of eating-related phenotypes within individuals. Amended IRB applications will be submitted prior to launching Phase 3.
The present invention relates to a capsule preparation of a traditional Chinese medicine for treating the thrombus of the blood vessel. A fresh earthworm is treated by chromatography and freeze-drying techniques, and earthworm extract containing fibrinolysin and an earthworm element is prepared; astragalus root extract containing astragalus root polysaccharide, astragalus root methyl glycoside, astragalus root total saponin and astragalus root flavone is extracted from astragalus root as a traditional Chinese medicine by a supercritical extraction technique; the dry powder of the earthworm extract, the dry powder of the astragalus root extract and starch are uniformly mixed according to a mass ratio of 2:1:50, and the capsule preparation of a traditional Chinese medicine for treating the thrombus of the blood vessel is prepared. The fibrinolysin and the earthworm element in the body of the fresh earthworm are fine purified and extracted by a biological engineering technique in the present invention. The capsule preparation not only can directly dissolve fibrin, but also can activate plasminogen into fibrinolysin to dissolve the fibrin, and can also reduce blood viscosity. The capsule preparation is favorable for the prevention of the formation of thrombus. The astragalus root extract is prepared by the supercritical extraction technique. The earthworm extract and the astragalus root extract are scientifically mixed, and are prepared into the capsule preparation of a traditional Chinese medicine for treating the thrombus of the blood vessel, and the capsule preparation has the functions of resisting thrombus, dissolving the thrombus, improving a microcirculatory system and increasing a blood flow.
PROBLEM TO BE SOLVED: To obtain the subject preparation for external use for skin capable of maintaining the elasticity of the skin and protecting the skin from excessive ultraviolet rays by using an extract from a specific plant having effects on suppression of collagen cross-linkage and further, as desired, using an ultraviolet ray protectant in combination. SOLUTION: This antiaging preparation for external use for skin is obtained by using an extract separated from a plant belonging to the genus Saxifraga of the family Saxifragaceae as an active ingredient. For example, the species anglica, apiculata and gluceriana are cited as the plant. The blending ratio of the extract is preferably 0.0001-10.0wt.%, especially preferably 0.001-1.0wt.%, based on the whole preparation for external use for the skin and expressed in terms of a dry substance. Furthermore, 0.01-30wt.%, especially 0.1-20wt.% ultraviolet ray protectant (a long-wavelength ultraviolet ray protectant is especially preferred) is preferably blended in the system. 4-Methoxy-4-t- butyldibenzoylmethane, etc., are cited as the long-wavelength ultraviolet ray protectant.  The preparation for external use for the skin is capable of suppressing the so-called optical aging due to collagen cross-linking especially by exposure to long-wavelength ultraviolet rays.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to biotechnology and concerns the use of lectin or lectin-like molecules for glycoproteids and antigenic molecules oligomerisation activation. Substance of the invention involves a composition presented by one or more noncovalent complexes eliciting an immune response in a patient where each complex contains heat shock protein, antigenic molecule and lectin, and where heat shock protein is glycolised, and where heat shock protein and antigenic molecule are originated from tumour tissue. There also presented methods of manufacturing of such molecular complexes and methods of using the compositions including such molecular complexes for prevention and treatment of cancer and infectious diseases. ^ EFFECT: advantage of the invention consists in increase in activity. ^ 34 cl, 9 ex, 2 tbl, 13 dwg
The present invention provides an acoustic wave biosensor adapted for the detection of endotoxins and processes for preparing same. The biosensor comprises a piezoelectric substrate modified with a self-assembling monolayer. Immobilized on the self-assembling monolayer is a biochemical probe (preferably, polymyxin B). Such biosensor is functionalized to detect endotoxins utilizing an electromagnetic piezoelectric acoustic sensor. According to another aspect of the present invention, there is provided polymyxin B immobilized beads, processes for preparing same, and neutralization cartridges comprising such beads for the treatment of endotoxemia. Finally, the present invention provide a theranostic circuit device for the treatment of endotoxmeia that utilizes one or more hemoperfusion cartridges and an acoustic wave biosensor.
The sample consisted of n=57 premature infants, n=27 in the study group and n=30 in the control group. Data were collected in two stages. In the first stage, mothers sang lullabies to the infants in the study group three times a week and touched them tenderly. In the second stage, developmental support program (GEDEP) was applied to the same infants for three months starting from the 40th week of gestation. The infants in the control group were given routine care. In data collection, Mother and Newborn Descriptive Information Form, Premature Infant Comfort Scale (PICS), Developmental Support Program Evaluation Form, GEDEP user guide form and Sound Decibel Measurement Device were used.
<P>PROBLEM TO BE SOLVED: To provide a pharmaceutical composition developed based on suggestion that a transcription factor, including NF-κB, is concerned in various kinds of diseases through expression of many genes which are under transcriptional control thereof and capable of efficaciously treating the diseases, especially skin diseases, including atopic dermatitis, vulgar psoriasis, contact dermatitis, keloid, bedsore, ulcerative colitis, and Crohn's disease.  <P>SOLUTION: This pharmaceutical composition is used for treating the skin diseases, wherein the composition contains at least one decoy and a pharmaceutically acceptable carrier. An NF-κB decoy, an STAT-6 decoy, an AP-1 decoy, and an Ets decoy are especially used as the decoy. Further, an oligonucleotide combining with the decoys is used as the decoy. A petroleum jelly, or the petroleum jelly containing stearyl alcohol or a liquid paraffin, is used as the carrier.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
While public health programs have demonstrated modest success in reducing the adolescent and young adult (AYA) risk for STI/HIV, significant health disparities remain. The risk of STI/HIV is not uniform among AYA. AYA residing in segregated urban communities with high STI prevalence and complicated sexual networks face even greater risk for disease and associated complications. Additional supports designed to increase engagement in care and reduce STI acquisition and transmissions are urgently needed to meet the sexual health and reproductive health goals for the nation. Overwhelmingly, AYA STI prevention interventions have targeted individuals and individual-level factors. While effective, these interventions do not adequately address other important influences affecting AYA risk for STI/HIV, such as partner or relationship influences on sexual decision-making and behavior. Partner notification and treatment is a key strategy for disease control and has previously been tested among adults for STI/HIV prevention work but has yet to be evaluated for AYA. Our prior research demonstrates that AYAs with complicated STIs are likely to notify their partners to seek treatment (88-92%); however, AYAs receiving brief behavioral interventions, relative to those receiving standard of care were 3 times more likely to be successful in arranging for their partner's treatment. Thus, partner interventions may hold promise for harnessing the power of relationship dynamics to enhance sexual decision-making, communication, and subsequent health behaviors. The investigators propose to pilot test an intervention designed to change sexual health outcomes by understanding partners and the learning environment related to sex \[COUPLES\] by simultaneously delivering two evidence-based STI/HIV prevention interventions Sister-to-Sister Teen and Focus on the Future. The simultaneous delivery of effective interventions will be augmented with a joint partner health education counseling session focused on enhancing communication and negotiation of safe sexual practices within the relationship. If successful, this pilot will support the development of a larger trial designed to evaluate the effectiveness of this approach in the busy primary care setting by providing evidence that AYA can and will safely engage their partners in a supportive primary care setting that integrates high quality treatment with evidence-based STI/HIV prevention interventions delivered by health educator teams.
AIM: This study explored the effect and mechanism of MAFF and HDAC6 on renal fibrosis and inflammation in lupus nephritis (LN).
METHODS: IL-33 treated renal epithelial cells and MRL/lpr mice were respectively used for in vitro and in vivo experiments. The expressions of HDAC6, MAFF, and KLF5 were measured in cells and renal tissues. Before and after cell transfection, the morphological changes in renal tissues were observed using Hematoxylin and eosin (H&E) and Masson staining. The proteinuria, serum creatinine (SCr), blood urea nitrogen (BUN), and double-stranded DNA (dsDNA) levels were detected by biochemical analysis. The expressions of fibrosis and inflammation related proteins (including α-SMA, Vimentin, IL-1β, IL-6, and TNF-α), p65, and iNOS were also detected. The relationship among MAFF, HDAC6, and KLF5 was determined by chromatin immunoprecipitation and dual luciferase reporter gene assay.
RESULTS: Renal tissues and cell models had elevated expressions of HDAC6 and KLF5, and decreased MAFF expression. HDAC6 suppression or MAFF overexpression led to suppression of proteinuria, SCr, BUN, and dsDNA levels, as well as attenuation of inflammatory infiltration and collagen deposition. HDAC6 can suppress MAFF expression via deacetylation to abolish its suppression of KLF5 expression, thus increasing KLF5 expression. In vivo and in vitro experiments showed the suppressive effect of HDAC6 suppression on renal fibrosis and inflammation can be abolished by KLF5 overexpression.
CONCLUSION: HDAC6 suppresses MAFF expression via deacetylation to elevate KLF5 expression, which consequently enhances fibrosis and inflammatory response in LN.